HSI1 22,410.80 -430.82 270.30B
HSCEI1 7,554.37 -135.97 89.05B
Back    Zoom +    Zoom - Block Traded
HSBC Research Raises INNOVENT BIO (01801.HK) TP to HKD133 as Johnson & Johnson Acquires Overseas Pipeline Partner Ollin
2026-11-20 17:17:49
HSBC Global Investment Research issued a research report stating that Johnson & Johnson recently announced the acquisition of Ollin for USD3.325 billion, including an upfront payment of USD2.2 billion and USD1.125 billion in regulatory and commercial milestone payments. Ollin is a partner of INNOVENT BIO (01801.HK). The broker maintained its "Buy" rating on INNOVENT BIO (01801.HK) and raised its TP from HKD130 to HKD133.

INNOVENT BIO (01801.HK) developed and licensed overseas rights of the VEGF/Ang2 bispecific antibody OLN324 to Ollin for global development. The project is currently undergoing global Phase III studies for eye diseases including diabetic macular edema (DME) and wet age-related macular degeneration (AMD). It marks INNOVENT BIO (01801.HK)'s first out-licensing deal in ophthalmology with a multinational pharmaceutical company. HSBC Global Investment Research estimated that INNOVENT BIO (01801.HK) holds about an 8% stake in Ollin and is entitled to a double-digit sales royalty, which could benefit the company and generate recurring income after OLN324 is launched overseas. If Phase III results replicate early-stage data, peak sales of OLN324 could reach USD5 billion.

The broker is also optimistic about the ramp-up in INNOVENT BIO (01801.HK)'s domestic sales and raised its revenue forecasts for 2026 to 2028 by 2% to 3% to RMB19.8 billion, RMB24.8 billion and RMB29.9 billion, respectively. Among them, GLP-1 revenue is forecast at RMB2.7 billion, RMB4.7 billion and RMB5.4 billion, respectively. Meanwhile, due to effective cost controls, the broker also raised its net profit forecasts by 13% to 20%, expecting net profit to reach RMB2.4 billion, RMB3.6 billion and RMB5 billion, respectively. (gc/u)~

AASTOCKS Financial News
Website: www.aastocks.com


This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.